Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma. Originally developed for intrave...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Larysa, Richter, Joshua, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richard, Shambavi, Tam, Lowena, Verina, Daniel, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841854/
https://www.ncbi.nlm.nih.gov/pubmed/33613930
http://dx.doi.org/10.1177/2040620720987075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841854/
https://www.ncbi.nlm.nih.gov/pubmed/33613930
http://dx.doi.org/10.1177/2040620720987075

Ejemplares similares